

Exhibit 14

VigiAccess

Note: Result is presented for the active ingredient, often including more than one brand name

Acetaminophen is an active ingredient

There are **175 116** reports with this active ingredient

Reported potential side effects

- › Blood and lymphatic system disorders (2%, 4 241 ADRs)
- › Cardiac disorders (2%, 5 177 ADRs)
- › Congenital, familial and genetic disorders (0%, 490 ADRs)
- › Ear and labyrinth disorders (0%, 991 ADRs)
- › Endocrine disorders (0%, 131 ADRs)
- › Eye disorders (3%, 9 148 ADRs)
- › Gastrointestinal disorders (10%, 27 939 ADRs)
- ▼ General disorders and administration site conditions (13%, 36 900 ADRs)
 - Drug ineffective (10 394)
 - Death (3 893)
 - Face oedema (2 729)
 - Pyrexia (2 540)
 - Pain (1 654)
 - Malaise (1 645)
 - Fatigue (1 477)
 - Therapeutic product effect incomplete (1 183)
 - Asthenia (1 125)
 - Oedema (940)
 - Drug interaction (851)
 - Therapeutic response unexpected (819)
 - Swelling (700)
 - Chest pain (696)
 - Feeling abnormal (672)
 - Swelling face (648)
 - Chills (640)
 - Condition aggravated (631)
 - Oedema peripheral (592)
 - Chest discomfort (493)
 - Therapeutic response decreased (480)
 - Drug ineffective for unapproved indication (472)
 - Unevaluable event (381)
 - Multiple organ dysfunction syndrome (377)
 - Hypothermia (361)
 - Adverse event (307)
 - No adverse event (300)
 - Peripheral swelling (295)
 - Feeling hot (290)
 - Gait disturbance (256)

VigiAccess


Crying (202)
 Infusion site pain (191)
 Therapeutic product effect decreased (175)
 Drug intolerance (169)
 Adverse drug reaction (166)
 Influenza like illness (163)
 General physical health deterioration (156)
 Illness (156)
 Discomfort (137)
 Localised oedema (129)
 Drug withdrawal syndrome (124)
 Feeling cold (107)
 Inflammation (103)
 Therapeutic product effect delayed (94)
 Gait inability (84)
 Therapy non-responder (78)
 Thirst (76)
 Brain death (75)

[Load more...](#)

- › Hepatobiliary disorders (5%, 13 940 ADRs)
- › Immune system disorders (2%, 5 824 ADRs)
- › Infections and infestations (1%, 3 857 ADRs)
- › Injury, poisoning and procedural complications (14%, 40 002 ADRs)
- › Investigations (4%, 12 156 ADRs)
- › Metabolism and nutrition disorders (1%, 3 910 ADRs)
- › Musculoskeletal and connective tissue disorders (1%, 3 429 ADRs)
- › Neoplasms benign, malignant and unspecified (incl cysts and polyps) (0%, 377 ADRs)
- › Nervous system disorders (7%, 18 761 ADRs)
- › Pregnancy, puerperium and perinatal conditions (0%, 813 ADRs)
- › Product issues (2%, 4 237 ADRs)
- › Psychiatric disorders (6%, 16 013 ADRs)
- › Renal and urinary disorders (2%, 4 573 ADRs)
- › Reproductive system and breast disorders (0%, 560 ADRs)
- › Respiratory, thoracic and mediastinal disorders (4%, 9 935 ADRs)
- › Skin and subcutaneous tissue disorders (18%, 50 186 ADRs)
- › Social circumstances (0%, 549 ADRs)
- › Surgical and medical procedures (0%, 750 ADRs)
- › Vascular disorders (2%, 5 351 ADRs)


Geographical distribution

[Chart](#) [Table](#)



Patient sex distribution

[Chart](#) [Table](#)




VigiAccess

Age group distribution

Chart


Table



ADR reports per year

Chart

Table



VigiAccess



VigiAccess is developed and maintained by the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre on behalf of WHO